These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 215527)
1. The genetic and antigenic basis for the IgA antibody response to Epstein-Barr viral capsid antigen. Ng MH; Ho HC; Kwan HC IARC Sci Publ (1971); 1978; (20):449-58. PubMed ID: 215527 [No Abstract] [Full Text] [Related]
2. Serum IgA antibodies to Epstein-Barr virus capsid antigen preceding symptoms of nasopharyngeal carcinoma. Ho HC; Kwan HC; Ng MH; de The G Lancet; 1978 Feb; 1(8061):436. PubMed ID: 75457 [No Abstract] [Full Text] [Related]
3. Epstein-Barr-specific IgA in nasopharyngeal cancer. Lancet; 1978 Jun; 1(8078):1345-6. PubMed ID: 78104 [No Abstract] [Full Text] [Related]
4. Epstein-Barr virus-related serology in nasopharyngeal carcinoma and controls. Henle W; Henle G; Ho JH IARC Sci Publ (1971); 1978; (20):427-37. PubMed ID: 215525 [No Abstract] [Full Text] [Related]
5. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC). Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561 [TBL] [Abstract][Full Text] [Related]
6. Presence of Epstein-Barr virus specific IgA in saliva of nasopharyngeal carcinoma patients: their activity, origin and possible clinical value. Desgranges C; de-The G IARC Sci Publ (1971); 1978; (20):459-69. PubMed ID: 215528 [No Abstract] [Full Text] [Related]
7. IgA antibodies to Epstein-Barr viral capsid antigens in saliva of nasopharyngeal carcinoma patients. Ho HC; Ng MH; Kwan HC Br J Cancer; 1977 Jun; 35(6):888-90. PubMed ID: 194619 [No Abstract] [Full Text] [Related]
8. [The clinical usefulness of the serological study of IgG antibodies and IgA against the antigens associated with the Epstein-Barr virus in patients with nasopharyngeal carcinoma]. Amador García JM; Mendoza Montero J; Expósito Hernández J; Salinero Hernández J; Esquivias López-Cuerpo J; Ballesteros García P Acta Otorrinolaringol Esp; 1992; 43(1):31-6. PubMed ID: 1316136 [TBL] [Abstract][Full Text] [Related]
9. [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx]. Mazeron MC Bull Cancer Radiother; 1996; 83(1):3-7. PubMed ID: 8679277 [TBL] [Abstract][Full Text] [Related]
10. [IgG and IgA antibodies to the Epstein-Barr virus and nasopharyngeal carcinoma]. Vera Sempere FJ Med Clin (Barc); 1992 May; 98(19):758-9. PubMed ID: 1318986 [No Abstract] [Full Text] [Related]
11. A prospective study of antibodies to Epstein-Barr virus DNase and viral capsid antigen for prognostication of patients with nasopharyngeal carcinoma. Hsu MM; Chen JY; Chen CJ Taiwan Yi Xue Hui Za Zhi; 1988 Oct; 87(10):984-8. PubMed ID: 2853721 [No Abstract] [Full Text] [Related]
12. Factors affecting serum IgA antibody to Epstein-Barr viral capsid antigens in nasopharyngeal carcinoma. Ho HC; Ng MH; Kwan HC Br J Cancer; 1978 Mar; 37(3):356-62. PubMed ID: 205232 [TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus is not associated with head and neck neoplasms other than nasopharyngeal carcinoma. Kottaridis SD; Goula I; Kiparissiadis P Neoplasma; 1982; 29(3):327-31. PubMed ID: 6290911 [No Abstract] [Full Text] [Related]
14. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups. Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990 [TBL] [Abstract][Full Text] [Related]
15. Serum IgA antibodies of Epstein-Barr virus (EBV)-related antigens. A new feature of nasopharyngeal carcinoma. Henle G; Henle W Bibl Haematol; 1975 Oct; (43):322-5. PubMed ID: 183692 [No Abstract] [Full Text] [Related]
16. The capsid antigen of Epstein-Barr virus in nasopharyngeal carcinomas: comparison of serum antibody titre, cellular antigen content and histopathology. Falser N Arch Otorhinolaryngol; 1984; 239(1):15-23. PubMed ID: 6318710 [TBL] [Abstract][Full Text] [Related]
17. [Demonstration of IgG- and IgA-antibodies against Epstein-Barr virus-associated antigens with a microtiter enzyme immunoassay system. The determination of serum antibodies against the viral capsid antigen and the early antigen complex in the sera of tumor and infectious mononucleosis patients]. Dölken G; Bitzer M; Bross KJ; Brugger W; Boldt C; Hirsch FW; Weitzmann U; Löhr GW Dtsch Med Wochenschr; 1984 Nov; 109(48):1837-43. PubMed ID: 6094138 [TBL] [Abstract][Full Text] [Related]
18. Malaria antibody levels in patients with nasopharyngeal carcinoma. Yadav M; Prasad U Southeast Asian J Trop Med Public Health; 1984 Jun; 15(2):234-7. PubMed ID: 6095462 [TBL] [Abstract][Full Text] [Related]
19. Antibodies to Epstein-Barr virus in patients with nasopharyngeal carcinoma and in comparison groups. Neel HB; Pearson GR; Taylor WF Ann Otol Rhinol Laryngol; 1984; 93(5 Pt 1):477-82. PubMed ID: 6093669 [TBL] [Abstract][Full Text] [Related]
20. Dynamics of Epstein--Barr virus antibody titre in nasopharyngeal carcinoma. Lynn TC; Tu SM Comp Immunol Microbiol Infect Dis; 1979; 2(2-3):201-5. PubMed ID: 228893 [No Abstract] [Full Text] [Related] [Next] [New Search]